M. Garff-Tavernier

发表

Persistence of CD16+/CD56−/2B4+ natural killer cells: A highly dysfunctional NK subset expanded in ocular myasthenia gravis

F. Bolgert, P. Debré, V. Leblond, 2006, Journal of Neuroimmunology.

ORIGINAL ARTICLE Analysis of CD16 þ CD56 dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

P. Debré, C. Dutertre, F. Davi, 2011 .

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

P. Debré, C. Dutertre, F. Davi, 2011, Leukemia.

CD56CD16 NK Cells: A Functional Intermediate Stage of NK Cell Differentiation

P. Debré, D. Duffy, V. Béziat, 2011 .

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

F. Davi, S. Choquet, K. Maloum, 2014, Leukemia.

IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL)

K. Hoang-Xuan, F. Davi, M. Tanguy, 2014 .

National standardization of ZAP‐70 determination by flow cytometry: The French experience

F. Ajchenbaum‐Cymbalista, R. Letestu, M. Ticchioni, 2007, Cytometry. Part B, Clinical cytometry.

Presence of multiple recurrent mutations revealed by targeted NGS confers poor trial outcome of relapsed / refractory CLL

A. Pettitt, S. Knight, Jenny C. Taylor, 2015 .

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

P. Feugier, S. Leprêtre, A. Schuh, 2014 .

Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospecific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods

M. Boubaya, S. Leprêtre, R. Letestu, 2014 .

Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia

F. Lacombe, M. Béné, O. Wagner-Ballon, 2013, British journal of haematology.

Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab

P. Debré, V. Leblond, H. Merle-Béral, 2012 .

behavior of blastic plasmacytoid

Marc C. Jacob, F. Jardin, B. Drénou, 2021 .

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1

P. Feugier, S. Leprêtre, F. Davi, 2017, Leukemia.